Biosimilar Pharmaceuticals

Comparison of the efficacy and safety of a proposed biosimilar MSB11456 with tocilizumab reference product in subjects with moderate-to-severe rheumatoid arthritis: results of a randomised double-blind study
Anna Zubrzycka-Sienkiewicz, Kamilla Klama, Martin Ullmann, Corinne Petit-Frere, Peter Baker, Joëlle Monnet, Andras Illes

RMD Open Feb 2024, 10 (1) e003596; DOI: 10.1136/rmdopen-2023-003596
Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System
Hugo Jourdain, Léa Hoisnard, Emilie Sbidian, Mahmoud Zureik

RMD Open Mar 2024, 10 (1) e003531; DOI: 10.1136/rmdopen-2023-003531
Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293
Roy M Fleischmann, Daniel F Alvarez, Amy E Bock, Carol Cronenberger, Ivana Vranic, Wuyan Zhang, Rieke Alten

RMD Open Apr 2021, 7 (2) e001578; DOI: 10.1136/rmdopen-2021-001578
Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects
Josef S Smolen, Roberto Caporali, Thomas Doerner, Bruno Fautrel, Fabrizio Benedetti, Burkhard Pieper, Minjun Jang

RMD Open Jun 2021, 7 (2) e001637; DOI: 10.1136/rmdopen-2021-001637
Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis
Jonathan Kay, Amy E Bock, Muhammad Rehman, Wuyan Zhang, Min Zhang, Noriko Iikuni, Daniel F Alvarez

RMD Open Sep 2022, 8 (2) e002423; DOI: 10.1136/rmdopen-2022-002423
Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry
Hafsah Nabi, Oliver Hendricks, Dorte Vendelbo Jensen, Anne Gitte Loft, Jens Kristian Pedersen, Søren Andreas Just, Kamilla Danebod, Heidi Lausten Munk, Salome Kristensen, Natalia Manilo, Ada Colic, Asta Linauskas, Pia Høger Thygesen, Louise Brot Christensen, Maren Høgberget Kalisz, Niels Lomborg, Stavros Chrysidis, Johnny Lillelund Raun, Marlene Andersen, Frank Mehnert, Niels Steen Krogh, Merete Lund Hetland, Bente Glintborg

RMD Open Nov 2022, 8 (2) e002560; DOI: 10.1136/rmdopen-2022-002560
Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar
Juliette Petit, Marie Antignac, Rose-Marie Poilverd, Régine Baratto, Sylvie Darthout, Sandra Desouches, Karine Louati, Nathalie Deparis, Francis Berenbaum, Catherine Beauvais

RMD Open Jan 2021, 7 (1) e001396; DOI: 10.1136/rmdopen-2020-001396

Log in using your username and password

Main menu

Log in using your username and password

You are here

Biosimilar Pharmaceuticals